137 related articles for article (PubMed ID: 19540857)
21. NK1 receptor-mediated endothelium-dependent relaxation and contraction with different sensitivity to post-receptor signaling in pulmonary arteries.
Miike T; Shirahase H; Kanda M; Kunishiro K; Kurahashi K
Vascul Pharmacol; 2009; 51(2-3):147-53. PubMed ID: 19539781
[TBL] [Abstract][Full Text] [Related]
22. Intrathecally-administered histamine facilitates nociception through tachykinin NK1 and histamine H1 receptors: a study in histidine decarboxylase gene knockout mice.
Yoshida A; Mobarakeh JI; Sakurai E; Sakurada S; Orito T; Kuramasu A; Kato M; Yanai K
Eur J Pharmacol; 2005 Oct; 522(1-3):55-62. PubMed ID: 16212954
[TBL] [Abstract][Full Text] [Related]
23. Localization of Fos-like immunoreactivity induced by the NK3 tachykinin receptor agonist, senktide, in the guinea-pig brain.
Yip J; Chahl LA
Br J Pharmacol; 1997 Oct; 122(4):715-25. PubMed ID: 9375969
[TBL] [Abstract][Full Text] [Related]
24. Mapping the binding pocket of a novel, high-affinity, slow dissociating tachykinin NK3 receptor antagonist: biochemical and electrophysiological characterization.
Malherbe P; Knoflach F; Marcuz A; Bohnert C; Weber M; Knust H; Ratni H; Spooren W; Ballard TM; Bissantz C
Neuropharmacology; 2014 Nov; 86():259-72. PubMed ID: 25107588
[TBL] [Abstract][Full Text] [Related]
25. Neurokinin3-R agonism in aged rats has anxiolytic-, antidepressant-, and promnestic-like effects and stimulates ACh release in frontal cortex, amygdala and hippocampus.
Schäble S; Topic B; Buddenberg T; Petri D; Huston JP; de Souza Silva MA
Eur Neuropsychopharmacol; 2011 Jun; 21(6):484-94. PubMed ID: 21342754
[TBL] [Abstract][Full Text] [Related]
26. Tachykinin NK(3)receptor involvement in anxiety.
Ribeiro SJ; Teixeira RM; Calixto JB; De Lima TC
Neuropeptides; 1999 Apr; 33(2):181-8. PubMed ID: 10657489
[TBL] [Abstract][Full Text] [Related]
27. Effect of melatonin on the vasopressin secretion as influenced by tachykinin NK-1 receptor agonist and antagonist: in vivo and in vitro studies.
Juszczak M; Boczek-Leszczyk E; Stempniak B
J Physiol Pharmacol; 2007 Dec; 58(4):829-43. PubMed ID: 18195491
[TBL] [Abstract][Full Text] [Related]
28. Blockade of tachykinin NK3 receptor reverses hypertension through a dopaminergic mechanism in the ventral tegmental area of spontaneously hypertensive rats.
De Brito Gariepy H; Couture R
Br J Pharmacol; 2010 Dec; 161(8):1868-84. PubMed ID: 20804497
[TBL] [Abstract][Full Text] [Related]
29. Tachykinin NK-1 and NK-3 selective agonists induce analgesia in the formalin test for tonic pain following intra-VTA or intra-accumbens microinfusions.
Altier N; Stewart J
Behav Brain Res; 1997 Dec; 89(1-2):151-65. PubMed ID: 9475623
[TBL] [Abstract][Full Text] [Related]
30. Central neurokinin 3 receptors increase systemic oxytocin release: interaction with norepinephrine.
Bealer SL; Flynn FW
Exp Neurol; 2003 Dec; 184(2):1027-33. PubMed ID: 14769397
[TBL] [Abstract][Full Text] [Related]
31. Tachykinin-depolarizations mediated by neurokinin-3 receptors in the hamster submandibular ganglion cells.
Yamada T; Endoh T; Suzuki T
Bull Tokyo Dent Coll; 1998 May; 39(2):123-6. PubMed ID: 9667146
[TBL] [Abstract][Full Text] [Related]
32. Activation of the cloned human NK3 receptor in Chinese Hamster Ovary cells characterized by the cellular acidification response using the Cytosensor microphysiometer.
Jordan RE; Smart D; Grimson P; Suman-Chauhan N; McKnight AT
Br J Pharmacol; 1998 Oct; 125(4):761-6. PubMed ID: 9831912
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological characterization of grooming induced by a selective NK-1 tachykinin receptor agonist.
Stoessl AJ; Brackstone M; Rajakumar N; Gibson CJ
Brain Res; 1995 Nov; 700(1-2):115-20. PubMed ID: 8624700
[TBL] [Abstract][Full Text] [Related]
34. Evidence for modulation of dopamine-neuronal function by tachykinin NK3 receptor stimulation in gerbil mesencephalic cell cultures.
Alonso R; Fournier M; Carayon P; Petitpretre G; Le Fur G; Soubrié P
Eur J Neurosci; 1996 Apr; 8(4):801-8. PubMed ID: 9081631
[TBL] [Abstract][Full Text] [Related]
35. SR142801 behaves as a tachykinin NK-3 receptor agonist on a spinal nociceptive reflex in the rat.
Couture R; Toma N; Barbot L
Life Sci; 2000; 66(1):51-65. PubMed ID: 10658924
[TBL] [Abstract][Full Text] [Related]
36. Nonpeptide tachykinin receptor antagonists. III. SB 235375, a low central nervous system-penetrant, potent and selective neurokinin-3 receptor antagonist, inhibits citric acid-induced cough and airways hyper-reactivity in guinea pigs.
Hay DW; Giardina GA; Griswold DE; Underwood DC; Kotzer CJ; Bush B; Potts W; Sandhu P; Lundberg D; Foley JJ; Schmidt DB; Martin LD; Kilian D; Legos JJ; Barone FC; Luttmann MA; Grugni M; Raveglia LF; Sarau HM
J Pharmacol Exp Ther; 2002 Jan; 300(1):314-23. PubMed ID: 11752131
[TBL] [Abstract][Full Text] [Related]
37. The NK-3 tachykinin receptor agonist senktide elicits 5-HT-mediated behaviour following central or peripheral administration in mice and rats.
Stoessl AJ; Dourish CT; Iversen SD
Br J Pharmacol; 1988 Jun; 94(2):285-7. PubMed ID: 2456111
[TBL] [Abstract][Full Text] [Related]
38. A novel role for tachykinin neurokinin-3 receptors in regulation of human bronchial Ganglia neurons.
Myers AC; Goldie RG; Hay DW
Am J Respir Crit Care Med; 2005 Feb; 171(3):212-6. PubMed ID: 15477495
[TBL] [Abstract][Full Text] [Related]
39. Effects of ageing on tachykinin function in the basal ganglia.
Stoessl AJ; Polanski E; Frydryszak H
Brain Res; 1993 Dec; 632(1-2):21-8. PubMed ID: 7511976
[TBL] [Abstract][Full Text] [Related]
40. Senktide, a selective neurokinin B-like agonist, elicits serotonin-mediated behaviour following intracisternal administration in the mouse.
Stoessl AJ; Dourish CT; Young SC; Williams BJ; Iversen SD; Iversen LL
Neurosci Lett; 1987 Oct; 80(3):321-6. PubMed ID: 2446214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
